USO 24276
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (TroFuse-032) MK2870-032
Disease Types: Breast Cancer Research
Eligibility Requirements:
• Untreated high-risk, early-stage, non-metastatic (M0) BC
• cT1c, N1-2 or cT2-T4a-d, N0-2
• Centrally confirmed TNBC or HR-low+/HER2- BC
• Bilateral tumors, multi-focal/multicentric, and inflammatory BC
are allowed, but all foci must have the same histology
• Tissue must be submitted for central confirmation of biomarkers
• No previous systemic therapy
For more information on this trial CLICK HERE .
Available at:
- Chesapeake
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Suffolk (Harbour View)
- Virginia Beach (Princess Anne)
- Williamsburg